Could Shire's ($SHPG) months-long pursuit of Baxalta ($BXLT) finally be coming to a close? That's the word from Reuters, which says the Dublin drugmaker is preparing to announce its acquisition--valued at about $32.5 billion--as early as Monday. The $48-per-share deal's cash component--which reportedly held things up as Shire sought a way to avoid taking on a tax liability related to Baxalta's summer spinoff from Baxter ($BAX)--will come in just below $20 per share, the news service reports. More